FDA PCAC Day 1 Recap: A Historic Vote for Peptide Access

If you've been following the peptide space, you already know that July 23, 2026, was circled on our calendars for months. Yesterday marked the first day of the highly anticipated Food and Drug Administration (FDA) Pharmacy Compounding Advisory Committee (PCAC) meeting. The stakes? Deciding whether to recommend returning several of the most popular and impactful peptides to the 503A Bulks List, which would allow state-licensed compounding pharmacies to legally produce them for patients with a prescription.

After hours of intense debate, presentations from FDA career scientists, and passionate public comments from physicians, pharmacists, and patients, the results of Day 1 are in. And for those of us who believe in the potential of peptide therapies, the outcomes are incredibly encouraging.

In a narrow but decisive series of votes, the committee recommended easing restrictions on four major peptides: BPC-157, KPV, TB-500, and MOTS-c.

Here is a detailed breakdown of what happened on Day 1, what the committee voted on, and what this means for the future of peptide medicine.

The Context: Why This Meeting Matters

Before we dive into the specific votes, it's important to understand the landscape. In recent years, peptides have exploded in popularity. From tissue repair and anti-inflammatory properties to metabolic support and longevity, the therapeutic potential of these amino acid chains has captured the attention of clinicians and patients alike.

However, many of these peptides have existed in a regulatory gray area. In 2023, the FDA reclassified several peptides, restricting compounding pharmacies from producing them. This drove a significant portion of the market underground, pushing consumers toward unregulated "research-only" vendors online — a scenario that presents real safety risks.

The goal of this PCAC meeting, championed in part by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., was to evaluate whether seven specific peptides should be added to the 503A Bulks List. Doing so would bring these therapies back into the light, allowing them to be produced safely by regulated compounding pharmacies under the supervision of licensed physicians.

Day 1 focused on four heavy hitters: BPC-157, KPV, TB-500, and MOTS-c.

The FDA's Stance vs. The Committee's Vote

Throughout the day, a clear divide emerged between FDA career scientists and the advisory committee members.

FDA staffers presented their scientific reviews, consistently arguing that there was a lack of rigorous, large-scale human clinical trials demonstrating the safety and efficacy of these peptides. They also raised concerns about standardization. Russell Wesdyk, an FDA official, noted that the agency struggles to define a universal chemical standard for some of these peptides, stating, "We can't create quality standards until we know what it is." [1]

However, the committee — which recently saw the addition of new members, many with clinical experience prescribing peptides — pushed back. The prevailing argument among the "yes" voters was that a lack of definitive, FDA-style clinical trial data does not equal a lack of efficacy. Furthermore, many argued that keeping these peptides restricted actually harms public health by forcing patients to source them from unregulated overseas vendors.

As Dr. Jessica Duncan, chief medical officer of IVIM Health, pointed out during the public comment period: "The question in front of you isn't whether people will use these. They already are. It's whether they use them with a doctor and a licensed pharmacy or completely alone." [2]

With that dynamic in play, let's look at the specific votes.

The Votes: BPC-157, KPV, TB-500, and MOTS-c

The committee voted on whether to recommend adding these peptides to the 503A Bulks List. It is worth noting that these votes are non-binding; the FDA will ultimately decide whether to adopt the recommendations, though they typically follow the committee's guidance.

### BPC-157 (Body Protection Compound-157)

The Vote: 8–6 in favor (1 abstention) [3]

BPC-157 is perhaps the most well-known peptide on the docket. Derived from a protein found in human gastric juice, it is widely used for its purported ability to accelerate the healing of tendons, ligaments, and gut tissue. The FDA specifically reviewed it for the treatment of ulcerative colitis.

Despite FDA scientists pointing to a lack of randomized controlled trials and citing a few adverse event reports, the committee voted in favor of BPC-157.

David Pope, Chief Pharmacy Officer at XiFin Pharmacy Solutions, summarized the pro-access sentiment clearly: "It's time to put this decision in the hands of the patient, the physician and the pharmacist. And I would agree with the idea that we need to keep this in America." [4]

### KPV (Lysine-Proline-Valine)

The Vote: 8–6 in favor (1 abstention) [3]

KPV is a naturally occurring tripeptide known for its potent anti-inflammatory and antimicrobial properties. It is often used for wound healing, gut health, and inflammatory skin conditions.

Similar to BPC-157, the FDA argued that there was insufficient data to support its widespread compounding. However, the committee again voted 8–6 to recommend adding it to the bulks list, emphasizing the need for safe, regulated access to anti-inflammatory alternatives.

### TB-500 (Thymosin Beta-4 Fragment)

The Vote: 8–6 in favor (1 abstention) [3]

Often paired with BPC-157 in what the community calls the "Wolverine stack," TB-500 is a synthetic fraction of the naturally occurring protein Thymosin Beta-4. It is highly sought after for its role in promoting cell migration, tissue repair, and wound healing.

The FDA's presentation noted a near-total lack of human clinical trials for TB-500. Yet, the committee, recognizing the widespread use of the peptide for injury recovery and the dangers of the gray market, voted in favor of allowing compounding pharmacies to produce it.

### MOTS-c (Mitochondrial Derived Peptide)

The Vote: 7–5 in favor (2 abstentions) [5]

MOTS-c is a fascinating peptide derived from mitochondrial DNA. It plays a crucial role in regulating metabolic functions and is currently being studied for its potential benefits in obesity, osteoporosis, and improving exercise capacity.

The vote for MOTS-c was slightly different, passing 7–5 with two abstentions. This reflects the more complex evidence base for metabolic peptides, but still resulted in a positive recommendation for broader access.

What This Means for the Future

The outcomes of Day 1 are a significant victory for medical freedom and patient safety. By recommending that BPC-157, KPV, TB-500, and MOTS-c be added to the 503A Bulks List, the PCAC has acknowledged a reality that many of us have known for years: these therapies have real potential, and patients deserve to access them safely under the guidance of a medical professional.

It is crucial to remember that this is not an FDA approval. The FDA still needs to review these recommendations and initiate a rulemaking process. As Dr. Brian Lee, an associate professor at the Keck School of Medicine who voted against the measures, cautioned, consumers should not perceive these votes as an endorsement of the peptides by the FDA [1].

However, this is a meaningful step in the right direction. If the FDA follows the committee's advice, compounding pharmacies will be able to produce these peptides under strict quality control standards — ensuring that patients receive exactly what their doctors prescribe, free from the contaminants and inconsistencies that plague the unregulated market.

Day 2 of the meeting (July 24) will cover three more peptides: Emideltide, Epitalon, and Semax. If Day 1 is any indication, we have reason to be cautiously optimistic.

We are witnessing a meaningful shift in how regulatory bodies view peptide medicine. The conversation is moving away from blanket restrictions and toward sensible regulation, patient safety, and clinical autonomy.

Stay tuned to PeptideScience101. I'll be back with a full recap of Day 2 and a deeper dive into what the next steps are for the FDA and the compounding pharmacy industry.

References

[1] Choi, J. (2026, July 23). *FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists*. The Hill. https://thehill.com/homenews/5987510-fda-committee-votes-peptides/

[2] Stone, W. (2026, July 23). *FDA panel backs easier access to peptides*. NPR. https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

[3] Lovelace Jr., B., & Miller, S. G. (2026, July 23). *FDA panel recommends easing restrictions on several peptides, including BPC-157*. NBC News. https://www.nbcnews.com/health/health-news/peptides-restrictions-ease-fda-panel-recommend-bpc-157-scientists-rcna588879

[4] Dunleavy, K. (2026, July 23). *In FDA compounding adcomm, advisers urge against restrictions on 1st of 7 peptides*. Fierce Pharma. https://www.fiercepharma.com/pharma/fda-adcomm-advisers-recommend-removal-restrictions-1st-7-peptides

[5] Roy, S., Niasse, A., & S K, S. (2026, July 23). *FDA advisers back first four of seven unapproved peptides under review for looser rules*. Reuters. https://www.reuters.com/legal/litigation/us-fda-advisers-weigh-restrictions-seven-peptides-industry-presses-expansion-2026-07-23/